ASH 2024 preview – multiple myeloma in focus
AbbVie looks to justify its faith in TeneoOne, and Bristol its phase 3 move with BMS-986393.
Tango missteps in PRMT5
The company abandons TNG908, but is still all in on the troubled target.
FDA red and green lights: October 2024
October's US approvals included Scemblix, Vyloy and Itovebi, while Lumakras was delayed.
Bristol changes tack in Claudin18.2
A tie-up with LaNova was terminated, perhaps in favour of a molecule originated by I-Mab.
Carvykti takes off
Meanwhile, Tecvayli stalls, but J&J still hopes for growth.
Regeneron’s fianlimab lung test approaches
The company reckons it can outdo Bristol’s relatlimab in first-line NSCLC.
The month ahead: October’s upcoming events
Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.
